Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia | Zendy

Shan L. Maude | Zendy; Theodore W. Laetsch | Zendy; Jochen Buechner | Zendy; Susana Rives | Zendy; Michael Boyer | Zendy; Henrique Bittencourt | Zendy; Peter Bader | Zendy; Michael R. Verneris | Zendy; Heather E. Stefanski | Zendy; Gary D. Myers | Zendy; Muna Qayed | Zendy; Barbara De Moerloose | Zendy; Hidefumi Hiramatsu | Zendy; Krysta Schlis | Zendy; Kara L. Davis | Zendy; Paul L. Martin | Zendy; Eneida R. Nemecek | Zendy; Gregory A. Yanik | Zendy; Christina Peters | Zendy; André Baruchel | Zendy; Nicolas Boissel | Zendy; Françoise Méchinaud | Zendy; Adriana Balduzzi | Zendy; Joerg Krueger | Zendy; Carl H. June | Zendy; Bruce L. Levine | Zendy; Patricia A. Wood | Zendy; Tetiana Taran | Zendy; Mimi Leung | Zendy; Karen T. Mueller | Zendy; Yiyun Zhang | Zendy; Kapildeb Sen | Zendy; David Lebwohl | Zendy; Michael A. Pulsipher | Zendy; Stephan A. Grupp | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia

Author(s) -

Shan L. Maude,

Theodore W. Laetsch,

Jochen Buechner,

Susana Rives,

Michael Boyer,

Henrique Bittencourt,

Peter Bader,

Michael R. Verneris,

Heather E. Stefanski,

Gary D. Myers,

Muna Qayed,

Barbara De Moerloose,

Hidefumi Hiramatsu,

Krysta Schlis,

Kara L. Davis,

Paul L. Martin,

Eneida R. Nemecek,

Gregory A. Yanik,

Christina Peters,

André Baruchel,

Nicolas Boissel,

Françoise Méchinaud,

Adriana Balduzzi,

Joerg Krueger,

Carl H. June,

Bruce L. Levine,

Patricia A. Wood,

Tetiana Taran,

Mimi Leung,

Karen T. Mueller,

Yiyun Zhang,

Kapildeb Sen,

David Lebwohl,

Michael A. Pulsipher,

Stephan A. Grupp

Publication year - 2018

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1709866

Subject(s) - lymphoblastic leukemia , medicine , leukemia , immunology

In a single-center phase 1-2a study, the anti-CD19 chimeric antigen receptor (CAR) T-cell therapy tisagenlecleucel produced high rates of complete remission and was associated with serious but mainly reversible toxic effects in children and young adults with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research